Idiopathic pulmonary fibrosis (IPF) is a progressive, lethal, and chronic lung disease. There
are no effective drug therapies for IPF. Hyperoside, a flavonoid glycoside, has been proven …

Pulmonary fibrosis (PF) could severely disrupt the normal lung architecture and function with
fatal consequences. Currently, there is no effective treatment for PF or idiopathic pulmonary …

Pulmonary fibrosis (PF) is a chronic and ultimately fatal interstitial lung disease of various
causes. The advent of nintedanib and pirfenidone provides treatment options for PF patients …

Aberrant activation of TGF-β1 is frequently encountered and promotes epithelial-
mesenchymal transition (EMT) and fibroblast activation in pulmonary fibrosis. The present …

Pulmonary fibrosis, a potentially fatal disease, results from acute and chronic interstitial lung
diseases. Fucoxanthin (Fx), a carotenoid found in brown seaweed, shows a wide range of …

Idiopathic pulmonary fibrosis (IPF) is a lethal lung disease with few treatment options and
poor prognosis. Emodin, extracted from Chinese rhubarb, was found to be able to alleviate …

Studies have shown that angiotensin-converting enzyme 2 (ACE2) plays modulating roles in
lung pathophysiology, including pulmonary fibrosis (PF) and acute lung injury. Pulmonary …

Pulmonary fibrosis (PF) is a chronic and progressive process of tissue repair. Azithromycin
(AZM) may be beneficial for the treatment of PF because AZM has anti-inflammatory and …

Pulmonary fibrosis, a progressive and lethal lung disease characterized by inflammation
and accumulation of extracellular matrix components, is a major therapeutic challenge for …

Bleomycin (BLM) is a chemotherapeutic agent which is associated with Idiopathic
pulmonary fibrosis (IPF) due to its chronic administration. Hesperidin, a bioflavonoid has …